Recombinant Human PD-L1/B7-H1/CD274(Fc fusion)

Description :

Recombinant Human Programmed Cell Death 1 Ligand 1 is produced by our Mammalian expression system and the target gene encoding Phe19-Thr239 is expressed with a Fc tag at the C-terminus.

Formulation :

Lyophilized from a 0.2 um filtered solution of 20mM PB, 150mM NaCl, pH7.4.

Purity :

Greater than 95% as determined by reducing SDS-PAGE.

Endotoxin :

Less than 0.1 ng/ug (1 IEU/ug) as determined by LAL test.

Reconstitution :

Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 米g/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Storage :

Lyophilized protein should be stored at ＜ -20℃, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7℃ for 2-7 days.
Aliquots of reconstituted samples are stable at ＜ -20℃ for 3 months.

Background :

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.